Evidence map›Paper›PMID 41114747›Full record

ArticleClinical oral investigations2025

Retrospective analysis of multimorbidity, polypharmacy, and drug interactions on postoperative outcomes in oral squamous cell carcinoma patients.

A Schmitz, C Reichardt, J Gierth, M Richter, F Mrosk, M Alfertshofer, L Knoedler, C Doll, F Hausmann, M Lee and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

A SchmitzDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany. alina-marie.schmitz@charite.de.
C ReichardtDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
J GierthDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
M RichterDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
F MroskDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
M AlfertshoferDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
L KnoedlerDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
C DollDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
F HausmannDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
M LeeDepartment of Gynecology with Center for Oncological Surgery, European Competence Center for Ovarian Cancer Campus Virchow Klinikum and Charité Comprehensive Cancer Center (CCCC), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gynecology with Center for Oncological Surgery, European Competence Center for Ovarian Cancer Campus Virchow Klinikum and Charité Comprehensive Cancer Center (CCCC), Augustenburger Platz 1, Berlin, 13353, Germany.
B KleikampDepartment of Anesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Hindenburgdamm 30, Berlin, 12203, Germany.
C RendenbachDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
M HeilandDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
S KoerdtDepartment of Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis retrospective study investigates the impact of multimorbidity, polypharmacy, and drug interactions on postoperative outcomes and patient management in individuals diagnosed with oral squamous cell carcinoma (OSCC). The study aims to identify treatment-related risks within surgical care pathways and explore the role of pharmacological complexity in patient prognosis. MATERIALS AND

methodsClinical data from OSCC patients undergoing surgical treatment were retrospectively analyzed. Key parameters included the presence of multiple chronic conditions (multimorbidity), the number and types of prescribed medications (polypharmacy), and the use of potentially inappropriate medications (PIMs) according to the PRISCUS list. Primary outcomes included postoperative complications, wound healing, readmission, reoperation rates, and mortality.

resultsMultimorbidity and polypharmacy were significantly associated with increased rates of postoperative complications, delayed wound healing, and higher rates of hospital readmission. PIMs were prescribed in 13.7% of patients and were linked to elevated mortality. Importantly, patients who did not receive PRISCUS-listed medications had a 55% lower risk of readmission and a 52.3% lower risk of reoperation, suggesting a potential benefit of medication optimization in perioperative care.

conclusionsThe findings emphasize the relevance of multimorbidity and complex medication regimens in influencing surgical outcomes in OSCC. Systematic preoperative risk assessment and medication review are critical to reducing complications and improving recovery.

Indexed as

Carcinoma, Squamous CellMouth NeoplasmsMultimorbidityPolypharmacyPostoperative ComplicationsAdultAgedAged, 80 and overDrug InteractionsFemaleHumansMaleMiddle AgedPatient ReadmissionReoperationRetrospective StudiesDrug interaction riskMultimorbidityOral squamous cell carcinomasOverall survivalPolypharmacyRecurrence rates

Identifiers

PMID41114747
PMCPMC12537594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.